The Sai Life Sciences IPO will open for subscription on Wednesday, December 11, 2024.
Sai Life Sciences aims to raise ₹3,042.62 crore through its IPO. This includes a fresh issue of 17,304,189 equity shares and an offer for sale of 38,116,934 shares, each with a face value of ₹1. The IPO is priced in the range of ₹522-₹549 per share, with a minimum lot size of 27 shares.
Retail investors need at least ₹14,823 to apply for 1 lot (27 shares). They can bid for a maximum of 13 lots, totalling 351 shares, within the ₹2,00,000 limit.
The proceeds from the fresh issue will be utilised for repaying or prepaying certain loans and for general corporate purposes. The company won’t receive funds from the offer for sale; these will go to the selling shareholders after deducting applicable costs and taxes.
Sai Life Sciences provides end-to-end research, development, and manufacturing services to biotech and pharma clients worldwide. Its offerings include chemistry, manufacturing, and control (CMC) services, along with contract research and development. The company operates globally, serving clients in the US, UK, Europe, and Japan.
KFin Technologies is the registrar for the Sai Life Sciences IPO, while Kotak Mahindra Capital, Jefferies India, Morgan Stanley India, and IIFL Securities are the lead managers.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
